Virologic response to treatment with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C in children

Medical Science Monitor

Volumn 16, Issue 12, 2010, Pages

  Pawłowska, Malgorzata ^a   Pilarczyk, Malgorzata ^a   Halota, Waldemar ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Children; Chronic hepatitis C; Pegifnalpha; Ribavirin; Virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA; ALPHA2B INTERFERON; MACROGOL DERIVATIVE;

ADOLESCENT; ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAMETERS OF MEASUREMENT AND ANALYSIS; POLYMERASE CHAIN REACTION; PREVALENCE; RECURRENT DISEASE; SCHOOL CHILD; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRUS LOAD; BLOOD; DRUG EFFECT; GENETICS; ABDOMINAL PAIN; CHILD CARE; CLINICAL ASSESSMENT TOOL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; FLU LIKE SYNDROME; HAIR LOSS; LEUKOCYTE COUNT; LEUKOPENIA; MODIFIED SCHEUER SCALE; NEURASTHENIA; OUTCOME ASSESSMENT; PROGNOSIS; RATING SCALE; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; VIROLOGY; WEIGHT REDUCTION;

ALANINE TRANSAMINASE; CHILD; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79751494192     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. El Bassiouny A, Abou-Shousha T, Moussa M et al: Hepatic mRNA expression of histone (H3): an early predictor of tumorgenic changes in chronic hepatitis C. Arch Med Sci, 2009; 5(4): 506-12
2. El Bassiouny A, El-Hassan SA, Moussa M et al: Down-regulation of intrahepatic CD16+ and CD56+ immune cells in chronic Hepatitis C virus infection and HCV-related hepatocellular carcinoma. Arch Med Sci, 2009; 5(3): 321-28
3. Elisofon S, Jonas MM: Hepatitis B and C in children; current treatment and future strategies Clin Liver Dis, 2006; 10(1): 133-48
4. Halota W, Pawłowka M: HCV infections In view of clinical practice. Med Sci Monit, 2004; 10(Suppl.1): 24-28
5. Hsu EK, Murray KF: Hepatitis B and C in children. Nat Clin Pract Gastroenterol Hepatol, 2008; 5: 311-20
6. Mohan N, Gonzales-Peralta R, Fujisawa T et al: Chronic Hepatitis C Virus Infection in Children. JPGN, 2010; 50: 123-31
7. Davison SM, Kelly DA: Management strategies for hepatitis C virus infection in children. Paediatr Drugs, 2008; 10: 357-65
8. Cesaro S, Bortolotti F, Petris MG et al: An Updated Follow-Up of Chronic Hepatitis C After Three Decades of Observation in Pediatric Patients Cured of Malignancy. Pediatr. Blood Cancer, 2010; 55: 108-12
9. Henderson WA, Shankar R, Feld JJ: Symptomatic and Patophysiologic Predicters of Hepatitis C Virus Progression in Pediatric Patients. Pediatr Infect Dis J, 2009; 28: 724-27
10. Wirth S, Pieper-Boustani H, Lang T et al: Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology, 2005; 41: 1013-18
11. Sokal EM, Bourgois A, Stephenne X et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol, 2010; 52: 827-31
12. Manns MP, McHutchinson JG, Gordon SC et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C; a randomized trial. Lancet, 2001; 358: 958-65
13. Wirth S, Ribes-Koninckx C, Calzado M et al: High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol, 2010; 52: 501-7
14. Schwarz K, Gonzales-Peralta RP, Murray KF et al: Peginterferon with or without ribavirin for chronic hepatitis C in children and adolescents: final results of the PEDS-C trial. Hepatology, 2008; 48(4 Suppl.) A: 242
15. Karnsakul W, Alford MK, Schwarz KB: Managing pediatric hepatitis C: current and emerging treatment options. Ther Clin Risk Manag, 2009; 5: 651-60
16. Gabriel A, Mietkiewski J, Ziółkowski A: Current morphological classification of chronic liver inflammation: its merits and problems. Pol J Pathol, 1999; 50(4 Suppl.1): 5-11
17. Sikorska K, Stalke P, Izycka-Świeszewska E et al: The role of iron overload and HFE gene mutations In the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. Med Sci Monit, 2010; 16(3): CR137-43
18. Al-Ali AJ, Owayed S, Al-Qabandi W et al: Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol, 2010; 9(2): 156-60
19. Bortolotti F, Verucchi G, Cammà C et al: Long-term course of chronic hepatitis C in children: from clearance to end-stage liver disease. Gastroenterology, 2008; 134: 1900-7
20. Liakina V, Speiciene D, Irnius A et al: Changes in hepatitis C virus infection routes and genotype distribution in a Lithuanian cohort with chronic hepatitis C. Med. Sci Monit, 2009, 15(4): PH17-23
21. Taliani G, Gemignani G, Ferrari C et al: Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology, 2006; 130: 1098-106
22. Moucari R, Ripault MP, Oulès V et al: High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol, 2007; 46: 596-604
23. Jara P, Hierro L, de la Vega A et al: Efficacy and safety of peginterferon- alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J, 2008; 27: 142-48
24. Hui CK, Monto A, Belaye T et al: Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum transaminases. Gut, 2003; 52: 1644-48